Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2010

View Archived Issues

Italian researchers discover new SMO receptor antagonists for cancer

Austrian scientists describe new GABA(A) receptor ligands

Daiichi Sankyo claims new ligands of voltage-dependent calcium channel subunit alpha2-delta

Pfizer discloses new PDE9A inhibitors

Praecis Pharma identifies novel ADAMTS-4 inhibitors

MK-4827 receives E.U. orphan drug status in ovarian cancer

Emergent BioSolutions acquires Trubion Pharmaceuticals

Topical nitroglycerin improves symptoms of chondrodermatitis nodularis helicis

Tenofovir vaginal gel reduces risk of HIV infection in women

Iontophoretically delivered terbinafine enters phase II trial in onychomycosis

Sipuleucel-T prolongs survival in phase III trial in castration-resistant prostate cancer

FT-23 attenuates diastolic dysfunction in model of diabetic cardiomyopathy

Allozyne partners with Sigma-Aldrich for cycloaddition chemistry

TLV and Emergent BioSolutions to codevelop H5 influenza vaccine

AVEO completes enrollment in phase III tivozanib trial in renal cell carcinoma

Dexamethasone intravitreal implant receives E.U. orphan drug status for noninfectious uveitis

Epitomics spins out new antibody therapeutics company, Apexigen

Humanetics receives licenses for medical radiation countermeasures

Novavax reports preclinical data on respiratory syncytial virus vaccine RSV-F

Stem Cell Therapeutics to begin phase IIa trial of hCG and EPO in traumatic brain injury

Syndax raises funds for ENCORE-301 trial in breast cancer

NIH begins phase I trial of its dengue vaccine Tetravax-DV

CeNeRx secures funds for phase II trial of new CX-157 formulation for depression

EMA validates CTI's expanded pediatric program for pixantrone in NHL

FDA grants orphan drug status to BC-819 in pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...